This excerpt taken from the PDLI 8-K filed Mar 17, 2005.
Okay. And then, finally, for Mark, this a question related to Retavase. And if you look at IMS data, the revenue has come down from 2002 to 2004. Could you let us know what has happened, you know, from what you expected and how are you going to change that? And what data do you think will enable you to do that?
Sure, to the extent I can answer without yet owning the rights to the product. The product, we believe, hit a peak sales in 2001 of approximately $110 million. And that was given full and aggressive promotion by a dedicated Centocor team. Subsequent to that, the product has moved over to Scios, another J&J subsidiary thats following the acquisition of Scios by J&J because of the cardiovascular focus of that company. Its our understanding that, particularly given some other priorities at Scios, that certainly over more than the past year, the product just has not had a dedicated promotional effort behind it. Notwithstanding that, its still got a reasonable share of the [INAUDIBLE] marketplace.
So, we feel that youre probably looking at base sales upon which we feel we can grow at a reasonable rate not really to the level it historically used to be but at a reasonable rate. And I think, as importantly, help us penetrate the ER for new opportunities of selling Cardene, because as Steve mentioned earlier, Cardene has a very good label, and is quite useful in a number of surgeries in the emergency room setting. And yet, weve not really had the number of reps and the product to be able to make an efficient call in that location. So now with two drugs of approximately the same size, weve made the sales force more efficient, and we think we can draw greater penetration for Cardene as a consequence.